What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants?
{{output}}
In this editorial we aim to provide potential therapeutic options in patients who do not benefit from treatment with CGRP(r) monoclonal antibodies. Based on current real-life studies and analysis of practical and economic aspects, we will analyze the potential... ...
